Givaudan reports accelerated organic growth in Q3 2026

Givaudan reported a significant acceleration in organic growth for the third quarter of 2026. The company achieved an organic sales increase of 8.6% in Q3, surpassing the consensus analyst expectation of 4.7% and exceeding the company's mid-term target range of 4% to 6%. For the first nine months of the year, total revenue reached 5.89 billion Swiss francs, representing a 2.6% increase compared to the previous year.

The growth was primarily driven by the Fragrance & Beauty segment, which saw 13.5% organic growth in Q3, bolstered by a 15.3% increase in luxury perfumery. Conversely, the Taste & Wellbeing (flavors) segment showed signs of recovery with 3.5% organic growth in Q3, up from 0.5% in the first half of the year, though performance in North America remained challenging due to weakness in functional ingredients and US tariff refunds.

In anticipation of these results, Research Partners downgraded Givaudan's rating from ‘Buy’ to ‘Hold’, citing recent price increases to an eleven-week high. However, other analysts remain optimistic; Barclays recently upgraded the stock to ‘Overweight’ with a price target of 3,850 Swiss francs, noting an attractive risk-reward ratio as market share concerns in fine perfumery may subside.